Provided by Tiger Fintech (Singapore) Pte. Ltd.

Alvotech

8.63
-0.1000-1.15%
Post-market: 8.880.2500+2.90%16:56 EDT
Volume:235.52K
Turnover:2.04M
Market Cap:2.69B
PE:25.46
High:8.84
Open:8.75
Low:8.54
Close:8.73
Loading ...

Alvotech, Teva Pharmaceutical's Bionsimlar Eye Disorder Potential Treatment Accepted for FDA Review

MT Newswires Live
·
18 Feb

BUZZ-Teva rises as FDA accepts to review biosimilar to eye disease drug Eylea

Reuters
·
18 Feb

Alvotech’s AVT06 Biosimilar Application Accepted by FDA

TIPRANKS
·
18 Feb

Alvotech and Teva’s BLA filing for AVT06 accepted by FDA

TIPRANKS
·
18 Feb

BRIEF-Alvotech And Teva Announce Filing Acceptance Of U.S. Biologics License Application

Reuters
·
18 Feb

Teva: Process to Obtain Regulatory Approval Is Anticipated to Be Completed in Q4 of 2025

THOMSON REUTERS
·
18 Feb

Alvotech Sa - Regulatory Approval Expected by Q4 2025

THOMSON REUTERS
·
18 Feb

Alvotech Sa - FDA Accepts for Review Bla for Alvotech's Biosimilar to Eylea

THOMSON REUTERS
·
18 Feb

Alvotech Sa - Regulatory Approval for Avt06 Expected by Q4 2025

THOMSON REUTERS
·
18 Feb

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for Avt06, a Proposed Biosimilar to Eylea® (Aflibercept)

THOMSON REUTERS
·
18 Feb

Alvotech Initiated at Buy by UBS

Dow Jones
·
15 Feb

Alvotech initiated with a Buy at UBS

TIPRANKS
·
14 Feb

Pagaya Technologies And 2 Other High Growth Tech Stocks In The US

Simply Wall St.
·
08 Feb

Alvotech, Teva Filing for Inflammatory Treatment Candidate Accepted for FDA Review

MT Newswires Live
·
27 Jan

Alvotech, Teva announce FDA accepts BLA for AVT05

TIPRANKS
·
27 Jan

Alvotech Sa - FDA Review Process Expected to Complete in Q4 2025

THOMSON REUTERS
·
27 Jan

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for Avt05, a Proposed Biosimilar to Simponi® and Simponi Aria® (Golimumab)

THOMSON REUTERS
·
27 Jan

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab)

GlobeNewswire
·
27 Jan

Alvotech's (NASDAQ:ALVO) largest shareholders are private equity firms with 34% ownership, private companies own 31%

Simply Wall St.
·
26 Jan

Private equity firms account for 34% of Alvotech's (NASDAQ:ALVO) ownership, while private companies account for 31%

Simply Wall St.
·
25 Jan